VACC Vaccibody AS

Nykode Therapeutics to Present at Jefferies Healthcare Conference

Nykode Therapeutics to Present at Jefferies Healthcare Conference

OSLO, Norway, May 30, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that its Chief Executive Officer, Michael Engsig, will present and host 1x1 meetings at the 2023 Jefferies Healthcare Conference in New York on Wednesday, June 7, 2023, at 10:00 a.m. ET / 4:00 p.m. CET.

The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website at .

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at .

Contact for Nykode Therapeutics ASA:

Chief Business Officer, Agnete Fredriksen

Nykode Therapeutics ASA

Nykode Therapeutics ASA

Oslo Science Park

Gaustadalléen 21

N-0349 Oslo, Norway

 



EN
30/05/2023

Underlying

VACCVaccibody AS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaccibody AS

Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
VACC VACCIBODY AS

Nykode Therapeutics (No_rec, TP: NOK) - A compromise

Today Nykode announced that Michael Engsig (CEO), Agnete Fredriksen (CSO and co-founder), and Harald Gurvin (CFO) have withdrawn their recent resignations and continue with the company. New board members have been proposed and key shareholders on the board have communicated they will propose a NOK1.00 DPS. We see the whole as a compromise.

04/16/25 April 16, 2025 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
VACC VACCIBODY AS

Nykode Therapeutics (No_rec, TP: NOK) - Recommendation and target pric...

Nykode announced the resignation of the board chair, board members and the senior management. As we have limited insight into the board’s plans, we have withdrawn our NOK4 target price and BUY recommendation.

03/27/25 March 27, 2025 1 EN
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Georg Tigalonov-Bjerke
03/27/25 March 27, 2025 1 EN
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Georg Tigalonov-Bjerke
03/02/25 March 2, 2025 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
VACC VACCIBODY AS

Nykode Therapeutics (Buy, TP: NOK4.00) - Transition on track

While the Q4 report contained no big surprises, Nykode Therapeutics said its transition into a “leaner, research- and technology-driven organisation” is on track. CFO Harald Gurvin said he believes it could reach the targeted cost base of cUSD20m per annum as soon as 2026. Following the strategic pivot, the company is focusing on: 1) asset generation; and 2) value creation through seeking early-stage partnerships. We reiterate our BUY and NOK4 target price.

02/27/25 February 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch